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ABSTRACT
Clinical studies evaluating targeted BRAFV600E inhibitors in advanced thyroid 
cancer patients are currently underway. Vemurafenib (BRAFV600E inhibitor) 
monotherapy has shown promising results thus far, although development of 
resistance is a clinical challenge. The objective of this study was to characterize 
development of resistance to BRAFV600E inhibition and to identify targets for effective 
combination therapy. We created a line of BCPAP papillary thyroid cancer cells 
resistant to vemurafenib by treating with increasing concentrations of the drug. The 
resistant BCPAP line was characterized and compared to its sensitive counterpart with 
respect to signaling molecules thought to be directly related to resistance. Expression 
and phosphorylation of several critical proteins were analyzed by Western blotting 
and dimerization was evaluated by immunoprecipitation. Resistance to vemurafenib in 
BCPAP appeared to be mediated by constitutive overexpression of phospho-ERK and 
by resistance to inhibition of both phospho-mTOR and phospho-S6 ribosomal protein 
after vemurafenib treatment. Expression of potential alternative signaling molecule, 
CRAF, was not increased in the resistant line, although formation of CRAF dimers 
appeared increased. Expression of membrane receptors HER2 and HER3 was greatly 
amplified in the resistant cancer cells. Papillary thyroid cancer cells were capable 
of overcoming targeted BRAFV600E inhibition by rewiring of cell signal pathways in 
response to prolonged vemurafenib therapy. Our study suggests that in vitro culture 
of cancer cells may be useful in assessing molecular resistance pathways. Potential 
therapies in advanced thyroid cancer patients may combine vemurafenib with 
inhibitors of CRAF, HER2/HER3, ERK, and/or mTOR to delay or abort development 
of resistance.
INTRODUCTION 
Thyroid cancer incidence in the United States is 
increasing and patients with metastatic and radioiodine-
resistant disease are in need of new treatments. Targeted 
therapy is a promising option for papillary thyroid cancer 
cases in which surgery and radioiodine are ineffective. 
In particular, targeting BRAFV600E, a mutation found in 
over one-half of papillary thyroid cancers and associated 
with worse prognosis, may provide clinical utility [1–3]. 
BRAF is a human gene coding a proto-oncogene protein 
called B-Raf which is a serine/threonine kinase. Results 
of an ongoing phase II clinical study including patients 
with metastatic or unresectable BRAFV600E-positive 
papillary thyroid cancer demonstrate that vemurafenib 
(BRAFV600E kinase inhibitor) has an anti-tumor 
effect when used as a monotherapy (Brose et al., 2013 
ECCO/ESMO/ESTRO Annual Meeting). These results 
are consistent with an earlier phase I clinical study, a 
case study involving a patient with advanced papillary 
thyroid cancer, and off-label use of vemurafenib (VMR) 
in 17 patients [4–6].
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Early clinical successes of VMR can be attributed 
to the mechanism of action it was designed for- inhibiting 
overactive BRAFV600E kinase within the pro-survival 
MAPK/ERK cell signaling pathway. ERK signaling 
serves as a link to convert extracellular stimuli into 
transcriptional programs affecting various processes such 
as cell growth, differentiation, proliferation, and apoptosis. 
Dysregulation of the ERK pathway occurs in one-third of 
all cancers and is mediated by genetic lesions resulting in 
events such as overexpression or constitutive activation 
of kinases and/or continuous production of activating 
ligands [7]. Within papillary thyroid cancer, mutations 
including BRAFV600E, RET/PTC and/or RAS are found 
in over 70% of cases. Each mutation contributes to ERK 
pathway activation and tends to be mutually exclusive 
within thyroid tumors [8, 9]. The most common mutation, 
BRAFV600E, results in a constitutively active kinase 
driving ERK signaling and thyroid cancer progression. 
Presence of the BRAFV600E mutation has been correlated 
with recurrence, resistance to radioiodine, and increased 
mortality [3, 10–13]. Inhibition of BRAFV600E kinase 
with VMR within thyroid cancer cells has been shown to 
inhibit cell proliferation and induce apoptosis [14–16]. 
A problem to overcome in the treatment of patients 
with small molecule inhibitors such as VMR is the 
development of drug resistance due to the adaptability 
of most cancers [17, 18]. Cancers treated with a single 
specific inhibitor of a ERK pathway protein will inevitably 
lose responsiveness to the drug and continue to express 
activated ERK [19]. The development of adaptive 
resistance can began shortly after treatment in cancer 
cells due to sudden inhibition of signaling leading to 
changes in feedback mechanisms. A signal rewiring is 
initiated and will persist if successful. It is also generally 
accepted that certain cells within a solid tumor are better 
able to accommodate the presence of a targeted inhibitor, 
perhaps due to a mutation or availability of alternative 
signaling proteins or pathways. Such cells will be clonally 
selected for in an evolutionary way after treatment with 
the inhibitor leading to drug-resistance of the tumor [17].
Based on data in literature and our prior findings, we 
hypothesize that determining targets of VMR resistance 
in thyroid cancer may be useful in developing rational 
combination therapy that limits resistance or exploits 
susceptibilities of resistant tumors. Successful clinical 
trials of VMR in melanoma patients demonstrated 
improved survival, although resistance often developed 
months after treatment [20, 21]. A number of studies found 
that resistance in these cases occurred mainly through 
reactivation of ERK signaling [22–31]. ERK reactivation 
can be propagated by increased expression or activity of 
upstream signaling molecules such as receptor tyrosine 
kinases (RTKs) in response to VMR treatment [32–34]. 
In addition, studies have attributed resistance to increased 
expression of kinases COT and CRAF, which are capable 
of contributing to ERK signaling independent of BRAF 
protein [22, 23]. It is expected that inhibitors of the kinases 
shown to be activated by persistent treatment with VMR, 
when used in combination therapy, may delay or abolish 
resistance to VMR.  
There are few studies which examine possible 
resistance mechanisms to BRAFV600E inhibition in 
thyroid cancer. One group found that VMR treatment 
led to increased transcription and expression of HER3 
receptor in thyroid cancer cells. These cells could be 
sensitized to BRAF inhibition with the addition of HER 
kinase inhibitor lapatinib [35]. In our study, we created 
resistance to VMR in vitro using BCPAP papillary thyroid 
cancer cells. We then analyzed differences in expression of 
ERK pathway signaling molecules in normal thyroid cells, 
papillary thyroid cancer cells, VMR-resistant papillary 
thyroid cancer cells, and inherently-resistant anaplastic 
thyroid cancer cells. Signaling molecules in the study 
included CRAF, HER2, HER3, ERK, and mTOR. We 
hypothesized that resistance develops through reactivation 
of ERK, mediated by increased upstream signaling and 
activation of molecules providing signaling alternatives 
to BRAFV600E. The goal of the present study was to 
identify target molecules that may contribute to VMR 
resistance in thyroid cancer cells. Further studies in which 
VMR is included in combination therapy may greatly 
benefit BRAFV600E-positive advanced thyroid cancer 
patients. 
RESULTS
In vitro resistance to vemurafenib develops in 
BCPAP cells 
We investigated resistance to BRAFV600E 
inhibition in vitro by treating BRAFV600E-positive 
papillary thyroid cells (BCPAP) with increasing 
concentrations of VMR (BRAFV600E inhibitor). Cells 
were initially susceptible to this drug and showed a lack 
of detectable phospho-ERK after 24 hour treatment, 
thereby demonstrating inhibition of signaling. Cells 
began to express detectable levels of phospho-ERK 
after the subsequent 12 μM treatment period and 
continued to show expression throughout the rest of 
the experiment, after treatment up to 16 μM VMR 
(Figure 1A). Reappearance of phospho-ERK indicates 
that cells adapted to activate ERK despite the VMR-
mediated block of BRAFV600E. These conditioned 
cells (resistant BCPAP) were maintained in culture 
and subjected to proliferation assays. Resistant BCPAP 
cells demonstrated diminished growth-inhibitory effects 
in response to VMR compared to BCPAP in our prior 
study (Figure 1B) [36]. In addition, an Alamar blue 
viability assay supported these results, since resistant 
cells maintained higher ability to reduce resazurin 
Oncotarget8678www.impactjournals.com/oncotarget
(an indicator of cell viability) compared to normal 
BCPAP cells over a range of vemurafenib concentrations 
(Figure 1C). At greater concentrations of VMR, the 
resistant BCPAP cells surpassed BRAF-wild-type Nthy-
ori 3-1 cells in terms of viability (Figure 1C). 
CRAF expression is not directly modulated 
by vemurafenib and resistance may be 
characterized by increased CRAF dimer 
formation 
Within the ERK signaling pathway, CRAF is a 
wild-type RAF isotype, and can transmit signals from 
GTP-bound RAS to MEK, which activates ERK. In this 
classical RAS-dependent kinase cascade, it is thought 
that dimer formation of CRAF is necessary to propagate 
signaling, which is not the case for mutated BRAFV600E 
signaling [37]. Since increased CRAF expression was 
shown to contribute to VMR resistance in melanoma, 
we analyzed CRAF expression and dimer formation in 
our thyroid cancer cells in response to this drug. Thyroid 
cells were treated with 10 µM VMR and collected at 
various time points including 1, 3, 6, 12, 24, 36, and 
48 hours. Cell lines included BRAF-wild-type normal 
thyroid cells (Nthy-ori 3-1), BRAFV600E-positive 
papillary thyroid cancer cells (BCPAP), VMR-resistant 
BCPAP, and BRAFV600E-positive anaplastic thyroid 
cancer cells (8505c). Throughout treatment, CRAF 
Figure 1: In vitro resistance to vemurafenib develops in BCPAP cells. (A) Cell lysates from BCPAP cells were collected after 
24 hour treatment periods with gradually increasing concentrations of vemurafenib (VMR), subjected to SDS-PAGE and analyzed by Western blot 
for expression of phospho-ERK1/2 at the end of the 45 day experiment. (B) BCPAP and resistant BCPAP cells (from A) were treated with 10 μM 
VMR for 36 hours and viable cells were counted by trypan blue exclusion assays. ****P < .0001. (C) Nthy-ori 3-1 normal thyroid cells, BCPAP, 
and resistant BCPAP cells were treated with varying concentrations of VMR for 96 hours and then incubated with Alamar blue for 4 hours. Percent 
absorbance is representative of the difference between measured absorbance at 570 nm and the control absorbance at 600 nm. Data in Figure 1B was 
published previously in Oncotarget. 2015; 6:39702–13.
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expression and phosphorylation remained constant in the 
four thyroid cell lines, indicating that expression is not 
directly modulated by VMR (Figure 2A–2D). 
To compare total CRAF expression among the 
thyroid cell lines and to determine if the expression of 
CRAF changes in response to VMR after resistance, 
we included all four cell lines on a Western blot after 
24 hours of treatment. We found no difference in 
overall CRAF expression among cell lines (Figure 2E). 
However, when an immunoprecipitation experiment 
was conducted using an anti-CRAF antibody to extract 
protein complexes from cell lysates, a greater amount of 
CRAF was isolated from VMR-resistant cells compared 
to normal BCPAP (Figure 2E). This data indicates that 
although total CRAF levels do not change, the formation 
of CRAF dimers may be increased in VMR-resistant 
BCPAP cells. Since activation of upstream RAS promotes 
RAF dimerization, we predicted that the increase in 
CRAF dimers occurred as a result of enhanced upstream 
signaling due to loss of negative feedback by ERK. In 
normal Nthy-ori 3-1 thyroid cells, an increase in CRAF 
dimers in response to 24 hour VMR treatment was 
observed, which may reflect the RAF inhibitor paradox, 
in which wild-type RAF dimer interactions are enhanced 
(Figure 2E).
BCPAP cells are sensitive to oscillatory inhibition 
of phospho-ERK by vemurafenib and resistant 
BCPAP cells are not
Interestingly, treating thyroid cells with VMR 
over various time points revealed an oscillatory pattern 
of ERK inhibition in BCPAP and 8505c. Inhibition 
occurred early at 1–3 hours and then phospho-ERK 
expression rebounded around 6 hours before inhibition 
ensued at 24 hours (Figure 2B, 2D). This phenomenon 
has been reported in the literature and was attributed 
to expression kinetics of DUSP5, an ERK phosphatase 
regulated by ERK activation [35, 38]. VMR-resistant 
BCPAP cells and BRAF-wild-type Nthy-ori 3-1 cells did 
not express this oscillatory pattern (Figure 2A, 2C). The 
resistant BCPAP line demonstrated only early inhibition 
Figure 2: Resistant BCPAP cells do not exhibit oscillatory inhibition of phospho-ERK and have increased CRAF 
dimers. (A–D) Nthy-ori 3–1, BCPAP, 8505c, and resistant BCPAP cells were subjected to 10 μM VMR for various time points and 
cytoplasmic extracts were collected and analyzed by Western blot for expression of phospho-ERK1/2, CRAF, phospho-CRAF, and GAPDH 
(loading control). (E) Cytoplasmic extracts from thyroid cell lines were collected after 24 hours untreated and treated with 10 μM VMR 
and analyzed by Western blot for comparison of CRAF expression. After being subjected to the same 24 hour treatment, thyroid cell lines 
were collected and lysed using 1% NP-40 buffer. Lysates were subjected to immunoprecipitation using anti-CRAF antibody, SDS-PAGE, 
and Western blot analysis for CRAF. 
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of ERK and then remained uninhibited throughout the 48 
hour treatment (Figure 2C). In contrast, normal BCPAP 
demonstrated oscillatory inhibition and cells were unable 
to survive treatment up to 48 hours (Figure 2B). The 
difference in expression pattern of phospho-ERK in 
response to VMR supports a role for ERK re-activation 
in adaptive resistance. However, sensitivity to oscillatory 
inhibition of phospho-ERK is not necessarily correlated 
with growth inhibition. When analyzing the anaplastic 
line (8505c), we found that these cells exhibit oscillatory 
ERK inhibition without detrimental effect on cell growth, 
suggesting pre-existing alternative signaling circuits in 
these cells (Figure 2D). 
Expression of receptor tyrosine kinases, HER2 
and HER3, is increased in vemurafenib-resistant 
BCPAP cells
To further investigate the role of feedback inhibition 
release caused by VMR, we analyzed expression 
of upstream membrane receptors by Western blot 
(Figure 3). We found that the resistant BCPAP cells 
expressed increased amounts of total HER2 compared to 
susceptible BCPAP cells (Figure 3A, 3B). BCPAP cells 
did not express detectable levels of HER3 protein in 
this experiment and the resistant BCPAP cells expressed 
relatively greater amounts. In addition, the resistant 
BCPAP cells responded to 24 hour VMR treatment 
by increasing phosphorylation of HER3 compared to 
untreated (Figure 3C). HER3 lacks tyrosine kinase activity 
itself, but becomes phosphorylated at tyrosine residues 
after forming heterodimers with other ErbB proteins such 
as HER2. The HER2/HER3 dimer is a potent activator 
of growth signaling pathways including MAPK. An 
intermediate expression level was seen in 8505c, as these 
cells expressed more HER2 and HER3 compared to 
BCPAP but less compared to resistant BCPAP. Expression 
of EGFR, which belongs to the same protein receptor 
family as HER2 and HER3, decreased slightly in the 
resistant BCPAP cells compared to normal BCPAP. 
Figure 3: Resistant BCPAP cells are characterized by increased expression of HER2 and HER3 and increased HER3 
phosphorylation in response to vemurafenib. (A) Whole cell lysates from thyroid cell lines were collected after 24 hours +/− 
10 μM VMR, subjected to SDS-PAGE, and analyzed by Western blot for expression of HER2, HER3, EGFR, and GAPDH (loading 
control). (B) Densitometry of Western blots in A was performed using ImageJ and expressed as percent expression compared to Nthy-ori 
3–1 after normalizing each sample to GAPDH. (C) Cell lysates were collected as in A and analyzed for expression of phospho-HER3 
(Tyr1197) and GAPDH as a loading control. (D) Densitometry of Western blots in C was performed using ImageJ and expressed as percent 
expression compared to untreated for BCPAP and resistant BCPAP samples. 
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Hyperactivation of ERK and resistance to 
phospho-mTOR inhibition characterize in vitro 
vemurafenib resistance in BCPAP cells
Since development of resistance appeared to be 
mediated through mechanisms involved in ERK signaling, 
we analyzed expression of key effector molecules, ERK 
and mTOR. We noted inhibition of phosphorylation 
of these molecules in normal BCPAP cells in response 
to 24 hour VMR treatment in a previous study [16]. 
When comparing expression levels of phosphorylated 
signaling proteins among cell lines, we found that the 
resistant BCPAP cells expressed a remarkably higher 
amount of phospho-ERK compared to normal BCPAP 
(Figure 4). VMR treatment decreased phospho-ERK 
expression in both normal and resistant BCPAP cells, 
although the detected amount of phospho-ERK in VMR-
treated resistant BCPAP was still greater than was seen 
in untreated BCPAP cells (Figure 4A). Resistant cells 
also had higher ratios of phospho-ERK to total ERK, 
indicating increased constitutive signal activation 
(Figure 4B). Normal BCPAP cells demonstrated phospho-
mTOR inhibition and a decreased ratio of phospho-mTOR 
to mTOR in response to VMR. However, the resistant 
BCPAP cells expressed an equal ratio of phospho-mTOR 
to total mTOR in untreated and VMR-treated samples, 
indicating resistance to VMR-mediated inhibition 
(Figure 4A, 4C). 
Resistant BCPAP are relatively resistant to 
vemurafenib-mediated inhibition of phospho-S6 
ribosomal protein compared to susceptible 
BCPAP 
Both ERK and mTOR signaling have been shown 
to contribute to the activation of molecules regulating 
translation, such as ribosomal S6 kinase (S6K) and its 
downstream substrate S6 ribosomal protein [39, 40]. We 
therefore investigated effects of VMR on S6 ribosomal 
protein expression and its activation in our VMR-sensitive 
and VMR-resistant thyroid cell lines. Results demonstrated 
that VMR treatment reduced the phospho-S6 ribosomal 
protein to total S6 ribosomal protein ratio more drastically 
in the susceptible BCPAP compared to resistant BCPAP 
(Figure 5A, 5B). Activation ratios of S6 ribosomal protein 
decreased to only 0.04 relative to untreated in BCPAP and 
decreased to 0.37 of the untreated ratio in resistant BCPAP, 
although BCPAP expressed greater amounts of phospho-S6 
ribosomal protein compared to resistant BCPAP in the 
untreated samples (Figure 5A, 5B). The relative ratio of 
S6 ribosomal activation after VMR treatment for 8505c 
anaplastic cells was 0.23 compared to untreated, indicating 
that the resistant BCPAP more effectively resisted inhibition 
of phospho-S6 ribosomal protein even compared to 8505c. 
The BRAF-wild-type thyroid cells (Nthy-ori 3-1) had a 
slightly increased ratio of phospho-S6 ribosomal protein to 
total S6 ribosomal protein after VMR treatment. 
Figure 4: Vemurafenib resistance is mediated by hyperactivation of ERK and loss of vemurafenib-mediated phospho-
mTOR inhibition. (A) Cytoplasmic extracts from thyroid cell lines were collected after 24 hours +/− 10 μM VMR, subjected to SDS-
PAGE, and analyzed by Western blot for expression of phospho-MEK, MEK, phospho-ERK1/2, ERK1/2, phospho-mTOR, and mTOR. 
(B) Activation of ERK1/2 was analyzed by calculating the ratio of phospho-ERK1/2 to ERK1/2 after normalizing to GAPDH and using 
ImageJ for densitometry. (C) Activation of mTOR was analyzed the same way as ERK in B. 
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DISCUSSION
In this study, we characterized cellular resistance 
to BRAFV600E inhibition in BCPAP papillary thyroid 
cancer cells in terms of signaling proteins. A main feature 
of resistant cells was hyperactivation of ERK signaling 
as demonstrated most clearly by increased expression 
of phospho-ERK and an increased ERK activation ratio 
compared to normal BCPAP (Figure 4A, 4B). Our data 
suggest that mechanisms contributing to enhanced ERK 
signaling may include increased expression of upstream 
HER2 and HER3 receptors (Figure 3) and formation of 
CRAF dimers (Figure 2E). Such activation leads to the 
signaling that bypasses BRAFV600E within this pathway. 
In addition, resistant cells appeared to be less vulnerable 
to inhibition of mTOR activation (Figure 4A, 4C) and 
inhibition of S6 ribosomal protein activation (Figure 5) 
by VMR. Investigating the capability of thyroid cancer 
cells to develop resistance to targeted BRAFV600E 
in vitro may lead to greater understanding of the 
mechanisms available to thyroid cancer cells within 
patient tumors and direct future aims to prevent or treat 
resistance through combination therapies. 
Our experiments involved forcing cells in culture to 
adapt to increasing concentrations of the targeted inhibitor. 
Although this rather short-term in vitro model of inducing 
VMR resistance may be seen as a limitation, our results 
exhibit concordance with prior in vitro and in vivo studies. 
For example, one of the most common mechanisms 
of adaptive resistance to targeted inhibitors is rebound 
expression of receptor tyrosine kinases (RTKs) as a result 
of loss of feedback inhibition from ERK [33, 41–42]. In 
Figure 5: Resistant BCPAP cells are less sensitive to vemurafenib-mediated inhibition of phospho-S6 ribosomal 
protein compared to BCPAP. (A) Cytoplasmic extracts from thyroid cell lines were collected after 24 hours +/− 10 μM VMR, 
subjected to SDS-PAGE, and analyzed by Western blot for expression of phospho-S6 ribosomal protein and S6 ribosomal protein. 
(B) Activation ratios of S6 ribosomal protein were calculated based on densitometry and normalized to the loading control and the 
untreated sample for each cell line. 
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our VMR-resistant thyroid cancer cells, we observed both 
increased expression of the membrane receptors HER2 
and HER3 and increased activation of HER3 in response 
to VMR. These results are consistent with the observation 
that short-term BRAFV600E inhibitor treatment also 
induced expression and activation of HER2/HER3 dimers 
in BRAF-mutant thyroid cancer cells [35]. Mechanisms 
contributing to ERK activation in the presence of 
pathway inhibitors are likely complex and cell-specific. 
The identification of potential drug targets that are 
characteristic of certain types of cancer, such as HER2/
HER3 in papillary thyroid cancer, will accelerate the 
process of developing effective combination therapies. Our 
study demonstrates that the creation of in vitro resistance 
may be a useful tool to identify resistance molecules for 
further investigation, especially if this technique is applied 
more broadly and/or with incorporation of patient-derived 
models. 
Although RAS activity was not measured, we 
predict that RAS activity increased during development 
of VMR resistance as a result of the increase in HER2 and 
HER3 receptors, which dimerize to potently activate RAS. 
Since activated RAS promotes the dimerization of wild-
type RAF proteins, our prediction agrees with the finding 
of increased CRAF dimers in VMR-resistant BCPAP cells 
compared to susceptible BCPAP. The formation of CRAF 
dimers offers a mechanism to directly bypass the inhibited 
BRAFV600E molecule and continue signaling through the 
ERK pathway in a BRAFV600E-independent manner.  
It is likely that BRAFV600E-positive thyroid cancer 
cells are capable of dynamically altering expression and 
signaling patterns of cellular proteins in many ways to 
gain resistance to VMR. The complex interaction of ERK 
and mTOR signaling in this process is of great interest and 
requires further study. These two pathways are thought to 
converge at the regulation of factors involved in translation 
initiation. ERK signaling activates the p90 ribosomal 
protein S6 kinases (RSKs) and mTOR signaling activates 
ribosomal protein S6 kinase (S6K) [41, 42]. Both RSK 
and S6K phosphorylate S6 ribosomal protein, which then 
interacts with tRNA, initiation factors, and mRNA [43]. 
S6 ribosomal protein is thought to enhance the affinity of 
ribosomes for mRNAs with 5′-terminal oligopyrimidine 
tracts, thus promoting translation initiation, and also 
has a role in regulating cell size [42]. Interestingly, 
convergence of ERK and mTOR signaling also occurs 
on another factor, eukaryotic translation initiation factor 
4B (eIF4B). One study found that both ERK and mTOR 
phosphorylate eIF4B at the same residue (Ser422), 
which increases the protein’s interaction with eukaryotic 
initiation factor 3 [44]. Our study shows that the VMR-
resistant BCPAP cells when treated with the drug had over 
9-fold higher proportion of the S6 ribosomal protein in the 
phosphorylated state compared to that of VMR-sensitive 
BCPAP cells (Figure 5B, 0.37:0.04). The rate of protein 
synthesis, thus translating to cell growth rate, was more 
than 9 times less suppressed by VMR in the resistant cells 
compared to in sensitive cells. 
 The pattern we observed in terms of activation 
of S6 ribosomal protein in our VMR-resistant BCPAP 
cells more closely resembles that seen with activation of 
mTOR compared to activation of ERK. While ERK was 
constitutively hyperactive within resistant BCPAP cells, 
activation of mTOR and S6 ribosomal protein was not 
increased in the resistant line, but less inhibited by VMR 
treatment compared to susceptible BCPAP. It is possible 
that the relatively refractory nature of S6 ribosomal protein 
activation in resistant cells is mediated by both ERK and 
mTOR, especially since activation of mTOR itself is 
inhibited by BRAFV600E inhibition in normal BCPAP. 
Hyperactive ERK may be contributing to the persistent 
mTOR phenotype. 
Characterization of development of resistance 
also agrees with results of our prior study investigating 
combination therapy using BRAFV600E and mTOR 
inhibitors in thyroid cancer cells [36]. Earlier, we found 
that the combination reduced cell viability in resistant 
BCPAP cells. In addition, the combination had a greater 
effect on VMR-sensitive BCPAP cells in that mTOR 
inhibitors sensitized these cells to cytotoxic effects of 
VMR. Taken together, the data suggests that proteins 
capable of mediating resistance in the presence of 
increasing concentrations of a targeted inhibitor may also 
be indicated as targets in susceptible cells. Determining 
rational targets to be inhibited in combination with existing 
kinase inhibitors is a growing topic of interest due to the 
potential for limiting resistance, enhancing apoptosis and/
or suspending tumor growth indefinitely. Within the RAF-
mutated cancers, researchers found that the combination 
of sorafenib (RAF inhibitor) and flavopiridol (pan-
CDK inhibitor) synergistically enhanced cytotoxicity in 
RAS/RAF mutant breast cancer cells [45]. In addition, 
treatment of sorafenib combined with the phytochemical 
fisetin (PI3K inhibitor) reduced tumor growth, inhibited 
proliferation and angiogenesis, and induced apoptosis in 
melanoma xenografts more effectively compared to each 
individual treatment [46]. Novel combination therapy is a 
concept that can be applied broadly among human cancers, 
is constantly evolving, and may provide a solution for 
targeted inhibitor resistance. 
While this study focuses on protein expression and 
cell signaling within thyroid cells, research in melanoma 
has identified additional means of resistance through 
genetic mutation in other ERK proteins such as NRAS, 
alternative splice patterns of BRAFV600E, and gene 
amplification of BRAFV600E [25, 28–31]. It is possible 
that genetic mutation occurred concurrently with signaling 
changes in our thyroid cells. The plasticity of responses 
to targeted therapy suggests that while targeting critical 
signaling molecule BRAFV600E will provide immediate 
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and potent antitumor effects, the eventual development of 
resistance must be combated with multifaceted inhibition. 
This inhibition may include multiple agents with different 




 Thyroid cell lines used in this study include Nthy-
ori 3-1 (immortalized normal thyroid cells), BCPAP 
(papillary thyroid cancer cells), and 8505c (anaplastic 
thyroid cancer cells).  Dr. Norman L. Eberhardt (Mayo 
Clinic, Rochester, MN) generously gifted the Nthy-ori 
3-1 cell line. BCPAP and 8505c cell lines were purchased 
from DSMZ in Braunschweig, Germany. All cell lines 
were cultured in Roswell Park Memorial Institute (RPMI)-
1640 supplemented with 10% fetal bovine serum (FBS), 
penicillin 10,000 IU/mL, streptomycin 10,000 μg/mL, and 
2  mM L-glutamine. 
Resistant BCPAP cell line
 VMR-resistant BCPAP cells were created by 
intermittently treating BCPAP cells with increasing 
concentrations of VMR (Chemietek, Indianapolis, IN). 
Cells were subjected to treatment for 24 hour periods, 
subcultured and allowed to grow to 70% confluence before 
the next treatment. After each treatment period, a portion 
of cells were collected for analysis in terms of phospho-
ERK expression. Resistant BCPAP cells were maintained 
in culture with intermittent treatments of 16 μM VMR. 
Alamar blue cell viability assay
Cells were plated at 4,000 cells per well in 96-
well plates and allowed to adhere overnight. Complete 
media was replaced with 100 µL phenol-red-free RPMI 
containing 5% charcoal dextran-treated FBS and various 
concentrations of VMR including 0, 10, 100, 1000, 
20000, and 50000 nM. Plates were incubated at 37°C for 
96 hours and then 10 µL Alamar blue was added to each 
well. Plates were incubated for 4 hours protected from 
light before optical density was measured at 570 nm and 
600 nm for control. 
Western blotting
 Thyroid cells were grown to 70% confluence in 
T75 flasks and complete media was replaced with 5% 
charcoal dextran-treated FBS-containing media for 
24 hours. Cells were treated with +/– 10 μM VMR for 
1, 3, 6, 12, and 24 hours. For whole cell lysates, cells 
were collected by gentle scraping with cell scrapers, 
subjected to radioimmunoprecipitation assay buffer (50 
mM Tris-HCl [pH 7.4], 150 mM NaCl, 0.2% sodium 
deoxycholate, 0.1% sodium dodecyl sulfate [SDS], 0.5% 
NP40, and 1 μM Pefabloc) and vortexed every 5 minutes 
for 30 minutes over ice. Lysates were centrifuged at 
14,000 rpm for 30 minutes at 4°C and each supernatant 
was collected. Cytoplasmic extracts were obtained using 
NE-PER Nuclear and Cytoplasmic Extraction Reagents 
kit (Pierce). Volumes containing 10 µg or 20 µg protein 
per sample were subjected to 12% SDS-polyacrylamide 
gel electrophoresis. Proteins on gels were transferred 
to Immobilon-P membranes for 2 hours at 220 mA in a 
transfer chamber. Membranes were blocked with 5% milk 
in TBST (10 mM Tris-HCl, pH 7.5, 200 mM NaCl, 0.05% 
Tween-20) for 1.5 hours at room temperature and then 
incubated overnight in primary antibodies (Cell Signaling) 
at 4° C. Membranes were washed three times with TBST 
for 5 minutes per wash and incubated with secondary 
antibody for 2 hours at room temperature. After 4 TBST 
washes of 10 minutes each, membranes were developed 
by enhanced chemiluminescence (Thermo Scientific) and 
detected on X-ray film. All densitometry was performed 
using the ImageJ program.
Immunoprecipitation
Thyroid cells were plated in T75 flasks and 
allowed to grow until 70% confluence. Complete media 
was replaced with 5% charcoal dextran-treated FBS-
containing media and flasks were incubated for 24 hours. 
Cells were treated for an additional 24 hours with +/– 
10 μM VMR. Cells were collected by gentle scraping, 
spun down, and subjected to 1% NP-40 lysis buffer 
on ice for 10 minutes with periodic mixing. Samples 
were centrifuged for 10 minutes at 14,000 rpm and 
4°C and supernatants were collected. GammaBind Plus 
Sepharose beads (GE Healthcare) were washed 3 times 
with PBS. CRAF antibody (BD Bioscience) was added 
to beads and the mixture was incubated for 2 hours at 
4°C with constant rotation. At the same time, 100 µg 
of sample lysate was also incubated for 2 hours at 4°C 
with constant rotation to pre-clear lysates. The beads 
coated with antibody were washed three times with PBS 
before the pre-cleared lysate was added to them. This 
mixture was incubated overnight in eppendorf tubes at 
4°C with constant rotation. The tubes were centrifuged 
for 10 minutes at 14,000 rpm and beads were washed 
three times in 1% NP-40 lysis buffer. Loading buffer 
was added to the samples. Samples were boiled for ten 
minutes and spun down. Supernatants were subjected 
to 12% SDS-polyacrylamide gel electrophoresis as in 
our prior studies and probed for CRAF with primary 
antibody (Cell Signaling). 
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